However, this BNIP3-dependent tumor suppression mechanism may be relevant only in the liver, where lipid accumulation promotes both nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), which are precursor diseases to HCC [87]. Here, BNIP3 is linked to metabolic dysfunction-associated steatohepatitis.